Tisheng Bio

Tisheng Bio (瑅盛生物) is a Chinese biotech startup in Frees VC's portfolio, focused on TCR drug development. Founder Li Yi has represented the company at industry events organized by Frees, including a September 2025 Shanghai salon on TCR technology development and translation co-hosted by the Shanghai Society of Bioengineering . The company was also listed among five Frees-backed biotech firms participating in a Suzhou biomedical innovation summit in early 2025 . elsewhere's corpus does not contain further details on Tisheng's pipeline, financing history, or founding date.